We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
Moderna’s two-strain shot will target both the original strain and BA.1 in step with European regulators
The chair of the $60bn US biopharma group explains how his approach to combining science with entrepreneurship led to the company’s creation
US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases
Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech
US prepares to roll out jabs to last age group without access once regulatory approval is received
US pharma company aims to roll out the new vaccine by late summer
Top finance director ousted after one day in job following emergence of probe at former employer
Exit of Jorge Gomez after only a day in the job is latest in string of executives to leave biotech group
Jorge Gomez leaves vaccine maker after former employer launches probe into financial reporting
US drugmaker says demand for ‘bivalent booster’ could lift jab sales in second half of 2022
Two top-10 shareholders say distribution problems not supply is reason for slower vaccination rates in low-income countries
Moderna’s chief says there is ‘massive oversupply’
Proxy advisers back shareholder resolutions as new shot shows promising results
Remuneration at the three big jab makers reflects surge in value of share options
Drugmaker says jab is safe and boosts immunity but had modest efficacy against Omicron
Switch in US company’s stance follows criticism over vaccine inequality in low- and middle-income nations
US drugmaker reports first annual profit and rejects concerns it is a ‘one product company’
Plus, renewed legal action over sustainability claims and a stark reversal of fortunes for European wind groups
Fractious World Trade Organization talks on overriding intellectual property rights look increasingly irrelevant
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
Activists and politicians push pharma company to cut prices and expand production for poorer countries
New mRNA technology could make jabs better-matched to different annual strains and improve efficacy
International Edition
